Dollar General, Dollar Tree and Kroger customers pay over $90 million a year in cash-back fees, federal agency finds

Dollar General, Dollar Tree and Kroger customers pay over  million a year in cash-back fees, federal agency finds


Key Points
  • Dollar General, Dollar Tree and Kroger have charged customers who ask for cash back in recent years.
  • Their cash-back fees amount to more than $90 million a year, Consumer Financial Protection Bureau reports.
  • Such fees may disadvantage those in banking deserts, where they don’t have easy access to cash for free. Retailers say they offer a lifeline to such consumers, who may not otherwise be able to get cash.



Source

Stocks making the biggest moves after hours: Cisco, Flutter Entertainment, Firefly and more
Finance

Stocks making the biggest moves after hours: Cisco, Flutter Entertainment, Firefly and more

Check out the companies making headlines in after-hours trading. Cisco — Shares of Cisco gained more than 7% in extended trading after the networking company posted better-than-expected profit and revenue for its fiscal first quarter. Cisco earned $1 per share, excluding items, on $14.88 billion in revenue, while analysts polled by LSEG expected 98 cents […]

Read More
Boston Fed President Collins advocates holding rates steady, sees ‘high bar’ for further cuts
Finance

Boston Fed President Collins advocates holding rates steady, sees ‘high bar’ for further cuts

Key Points Boston Fed President Susan Collins said she will be reluctant to support further rate cuts anytime soon with inflation still high and policymakers hampered by a lack of data. “I see several reasons to have a relatively high bar for additional easing in the near term,” said Collins, a voter this year on […]

Read More
Stocks making the biggest moves midday: Goldman Sachs, AMD, Oklo, Circle Internet & more
Finance

Stocks making the biggest moves midday: Goldman Sachs, AMD, Oklo, Circle Internet & more

Check out the companies making the biggest moves midday: Alkermes — The biotech company dropped 9% as traders weighed phase 2 trial results for its ALKS 2680 drug, which aims to treat narcolepsy. While the company will be advancing the drug to a Phase 3 trial, a higher range of doses or a split dosing […]

Read More